Small Doses: September 23 to September 27

Marstacimab-hncq is the first non-factor and once-weekly treatment available for patients with hemophilia B and promises to reduce the burden of care.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the state level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

The approval is supported by results from phase 3 multi-regional clinical trials conducted in patients with plaque psoriasis.

Drug Topics discussed independent pharmacy advocacy and PBM reform on the federal level with Miguel Rodriguez, Executive Vice President and general counsel for American Pharmacies.

In an interview with Drug Topics, TaQuina Warren, PharmD, discussed what it means to serve her community and how she has garnered a reputation within her profession.

Individuals living in rural areas can benefit from pharmacy-based pre-exposure prophylaxis programs.